Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00224133 · ClinicalTrials.gov registry record · Phase 3
The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used for 9 Months
A Phase 3 study of Benign Prostatic Hyperplasia, sponsored by Watson Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 661
- Enrollment target
- 20
- Study locations
NCT00224133: Completed Phase 3 study of Benign Prostatic Hyperplasia, sponsored by Watson Pharmaceuticals.
NCT00224133 is a Phase 3 study of Benign Prostatic Hyperplasia that has completed, run by Watson Pharmaceuticals. The registered enrollment target is 661 participants, above the 529-participant average among 29 other Benign Prostatic Hyperplasia trials with a reported enrollment target (25% higher). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00224133, a Phase 3 study of Benign Prostatic Hyperplasia, has completed, sponsored by Watson Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 661 participants
- Enrollment target
- 20
- Study locations
Study Summary
A new drug for benign prostatic hyperplasia is used for 9 months to determine its long-term safety.
Primary Outcome
All reported adverse events were recorded. Clinically significant abnormal laboratory values or other clinical findings upon examination were also recorded as adverse events.
Conditions Studied
Interventions
- DRUG Silodosin
Study Locations (20)
California
- - Anaheim
- - Carmichael
- - Culver City
- - Fresno
- - Irvine
- - La Jolla
- - Laguna Woods
- - Long Beach
- - Newport Beach
- - San Bernardino
- - San Diego
- - Tarzana
- - Torrance
Alabama
- - Birmingham
- - Huntsville
Colorado
- - Aurora
- - Wheat Ridge
Arizona
- - Tucson
Connecticut
- - Waterbury
Florida
- - Aventura
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 661 participants |
| Start Date | 2005-09 |
| Est. Completion | 2007-04 |
| Phase | Phase 3 |
What the finished NCT00224133 record still lists
NCT00224133 is an interventional study that assigns participants to a tested intervention. The registered 661 participants enrollment target is mid-sized for trials with a published cap, above the 529-participant average among 29 other Benign Prostatic Hyperplasia trials with a reported enrollment target (25% higher).
The record links to 1 condition, with Benign Prostatic Hyperplasia appearing as the primary indexed condition, and to 1 intervention - of which Silodosin is the first listed.
NCT00224133 names 20 study sites across 6 states, led by California, Alabama, Colorado.
Frequently Asked Questions
What is clinical trial NCT00224133 about?
NCT00224133 is a clinical study titled "The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used for 9 Months". A new drug for benign prostatic hyperplasia is used for 9 months to determine its long-term safety.
What is the current status of trial NCT00224133?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 661 participants. The study started on 2005-09. Estimated completion is 2007-04.
What conditions does trial NCT00224133 study?
This clinical trial studies the following conditions: Benign Prostatic Hyperplasia.
What interventions are being tested in trial NCT00224133?
The interventions under investigation include: Silodosin (DRUG).
Who is sponsoring clinical trial NCT00224133?
This trial is sponsored by Watson Pharmaceuticals, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00224133 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Benign Prostatic Hyperplasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00224133's enrollment target sits among peer trials
661 4th of 29 higher than 26 of 29 other Benign Prostatic Hyperplasia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Benign Prostatic Hyperplasia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Tadalafil in Men With Benign Prostatic Hyperplasia Symptoms Who Are Being Treated With Alpha Blockers
COMPLETED · Phase 3
-
Study to Treat Patients Who Have Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) With Tadalafil Daily
COMPLETED · Phase 3
-
Customized TULSA-PRO Ablation Registry
RECRUITING
-
OPtilume™ BPH Catheter SystEm for Treatment of Men eXperiencing Symptomatic BPH
RECRUITING
-
Ambulatory Long Length URodynamics Evaluation
RECRUITING · NA
-
Safety and Effectiveness of the Optilume® BPH Catheter System in a Post-Market Study
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05254743 · 662 participants · Phase 3
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- NCT01185132 · 660 participants · Phase 3
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
- NCT03346694 · 660 participants · NA
Reducing Surgical Site Infection Rates Using an Alternative Sternal Dressing
- NCT05407636 · 660 participants · Phase 3
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia